DOI: 10.1161/circ.148.suppl_1.12114 ISSN: 0009-7322

Abstract 12114: Advancing Heart Failure Knowledge and Therapies Through a Multicenter Registry and Innovative Platform for Extended Outpatient Hemodynamic Monitoring: The Hemodynamic Frontiers in Heart Failure (HF 2

Timothy Jordan, Kartik Munshi, Margaret Mcdermott, Evan D Muse, Jacob Abraham, maya guglin, Hirak Shah, Arvind Bhimaraj, Monique R Robinson, Rola Khedraki, Patrick McCann, Elizabeth Volz, Guha Ashrith, Orvar Jonsson, Kunjan A Bhatt, Andrew J Sauer, Mosi K Bennett, Terrie A Benjamin, Marat Fudim, J Thomas Heywood
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Background: Hemodynamic Frontiers in Heart Failure (HF 2 ) is a multicenter research consortium of institutions with active remote pulmonary artery pressure monitoring programs that aims to promote research in this field. The consortium recently created a registry of patients with pulmonary artery hemodynamic (HD) monitors (HDM) to facilitate the research mission.

Goals/Aims: HF 2 registry aims to collect demographic, clinical, laboratory, echocardiographic and HD data from HDM patients to create a test bed to advance scientific knowledge about ambulatory HD monitoring and quickly evaluate new therapies.

Methods: HF 2 includes patients aged >18 who would have been implanted with a HDM as per FDA indications of NYHA Class III HF diagnosis with a prior hospitalization or patients with NYHA Class II or BNP elevation without hospitalization. HF 2 registry data warehouse rests through University of Kansas Medical Center (KUMC) and was approved by their institutional review board (IRB) board followed by local IRBs at participating institutions with required Data use agreements. Institutions report data into the electronic registry database using REDCap, housed at KUMC.

Results: This initial data set includes 254 patients implanted from 2019 until May 2023. See Table 1 for initial demographic, comorbidity, laboratory, echocardiographic, and medication data. See Table 2 for HD measurements at time of implant.

Conclusion: A real-world registry/test bed of patients with HDM can evaluate long-term outcomes in such patients, provide data in unique patient groups, and provide an opportunity to evaluate HD effects of new HF therapies in rapid turnaround cross over trials.

More from our Archive